Why the study?
Do CYP2C19 mutations increase the risk of recurrent cardiovascular events or high on-treatment platelet reactivity in Arab cardiovascular disease patients using clopidogrel?
Do CYP2C19 mutations increase the risk of recurrent cardiovascular events or high on-treatment platelet reactivity in Arab cardiovascular disease patients using clopidogrel?
Answers are grounded in this paper and cite their sources.
In Arab populations, carriers of CYP2C19*2 and *3 alleles have an approximately 3-fold increased risk of recurrent cardiovascular events when treated with clopidogrel, highlighting the potential utility of pharmacogenetic testing in this demographic.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sue Barlow (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: